SLV-154 Treatment of Metastatic Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with metastatic solid tumors.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Dobry stan ogólny (zdolność do codziennych czynności)
- •Potwierdzony nowotwór litý (guz stały) jednego z wymienionych typów
- •Przerzuty nowotworu, które się rozprzestrzeniają mimo leczenia
- •Widoczny guz do zmierzenia na zdjęciach
- •Wcześniejsze leczenie przeciwnowotworowe (chemioterapia, leki celowane lub inne)
- •Próbka tkanki nowotworowej z biopsji lub próbka zarchiwizowana
- •Prawidłowe wyniki badań krwi, wątroby i nerek
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (10)
Hoag Memorial Hospital Presbyterian
Newport Beach, United States
Washington University
St Louis, United States
Astera Cancer Care
East Brunswick, United States
Memorial Sloan Kettering Cancer Center
New York, United States
University Hospitals Cleveland Medical Center
Cleveland, United States
MD Anderson Cancer Center
Houston, United States
Oncology Consultants
Houston, United States
Mays Cancer Center; University of Texas Health San Antonio
San Antonio, United States
University of Washington / Fred Hutchinson Cancer Center
Seattle, United States
Northwest Medical Specialties, PLLC
Tacoma, United States
Trial contact
Hong Ren, MD
Langdon L Miller, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.